As evidence by these results of the trial, the U.S. Food and Drug Administration has approved crizotinib for the treatment of children and young adults with relapsed/refractory (R/R) ALK‐rearranged ALCL. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.